Jakob Dynnes Hansen has more than 25 years of combined experience from biotech and financing. Prior to joining Acesion, he was the CFO for more than 9 years at Evolva, a Swiss public biotech company. At Evolva, he played a key role in the company’s listing in 2009 and several subsequent financings. Previously, he was CFO at two Danish biotech companies, Nuevolution and Zealand Pharma. Before moving into biotech, Mr Hansen spent nine years as senior member of the Corporate Finance Team at Unibank (now Nordea). Prior to Unibank, Jakob was Head of Market Research at Novo Nordisk and he has worked for the United Nations (UNIDO) in Indonesia. Jakob holds an MSc in Economics from the University of Copenhagen and an MBA from INSEAD.
Biotech and financing